Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, Inc. (TBPH), sold 46,600 shares at $13.92 ($650K) on 2026-03-16, disclosed to the SEC on 2026-03-18.
Scheduled sale ($650k) by SVP, COMM & MEDICAL AFFAIRS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.92 | 7,766 | $108K | 16.6% |
| 2 | $13.92 | 7,767 | $108K | 16.6% |
| 3 | $13.92 | 7,766 | $108K | 16.6% |
| 4 | $13.92 | 7,767 | $108K | 16.6% |
| 5 | $14.00 | 15,534 | $217K | 33.5% |
| Total | $13.95 avg | 46,600 |
| $650K |
| 100% |
| Filing → |
| TBPH | SELL | 2025-12-05 | $1.2M | — | Filing → |
| TBPH | SELL | 2025-07-16 | $174K | — | Filing → |
| TBPH | SELL | 2025-06-04 | $264K | — | Filing → |